Litcius/Paper detail

Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial

Jhon Rojas, Elisa de Lazzari, Eugènia Negredo, Peré Domingo, Juan Tiraboschi, Esteve Ribera, Nadia Abdulghani, Jordi Puig, María Gracia Mateo, Daniel Podzamczer, Maria Mar Gutierrez, Roger Paredes, Bonaventura Clotet, José M. Gatell, José Luís Blanco, Estebán Martínez

2021The Lancet HIV31 citationsDOI

Topics & Concepts

DolutegravirMedicineLamivudineRegimenPopulationInternal medicineClinical endpointViral loadEmtricitabineClinical trialAdverse effectAntiretroviral therapyHuman immunodeficiency virus (HIV)ImmunologyHepatitis B virusVirusEnvironmental healthHIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatments
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial | Litcius